AR122781A1 - Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridinilo - Google Patents
Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridiniloInfo
- Publication number
- AR122781A1 AR122781A1 ARP210101797A ARP210101797A AR122781A1 AR 122781 A1 AR122781 A1 AR 122781A1 AR P210101797 A ARP210101797 A AR P210101797A AR P210101797 A ARP210101797 A AR P210101797A AR 122781 A1 AR122781 A1 AR 122781A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- stereoisomer
- salt
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un proceso para la preparación de un compuesto de fórmula (1) o un estereoisómero o sal del mismo, cada uno de R¹ᵃ y R¹ᵇ es independientemente hidrógeno, halógeno, alquilo C₁₋₃ no sustituido, haloalquilo C₁₋₃ no sustituido, alcoxi C₁₋₃ no sustituido, -CN, cicloalquilo C₃₋₆ no sustituido o espirocicloalquilo C₃₋₆ no sustituido; cada R² es independientemente halógeno, hidroxilo, -CN, alquilo C₁₋₃ no sustituido, haloalquilo C₁₋₃ no sustituido o alcoxi C₁₋₃ no sustituido; m es 0, 1 ó 2; y n es 1, 2 ó 3; el proceso comprende: (a) poner en contacto un compuesto de fórmula (2), o un estereoisómero o sal del mismo con un ácido sulfónico para formar un compuesto de fórmula (3); o un estereoisómero o sal del mismo, (b) poner en contacto el compuesto de fórmula (3) o un estereoisómero o sal del mismo con una base para formar el compuesto de fórmula (4); o un estereoisómero o sal del mismo, (c) hidrogenar el compuesto de fórmula (4) o un estereoisómero o sal del mismo para formar un compuesto de fórmula (5); o un estereoisómero o sal del mismo, y (d) poner en contacto el compuesto de fórmula (5) o un estereoisómero o sal del mismo con un compuesto de fórmula (6); para formar de este modo un compuesto de fórmula (1) o un estereoisómero o sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046216P | 2020-06-30 | 2020-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122781A1 true AR122781A1 (es) | 2022-10-05 |
Family
ID=77022288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101797A AR122781A1 (es) | 2020-06-30 | 2021-06-28 | Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridinilo |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11873305B2 (es) |
| EP (1) | EP4172144A2 (es) |
| JP (2) | JP7419503B2 (es) |
| KR (1) | KR20230031321A (es) |
| CN (1) | CN115916750A (es) |
| AR (1) | AR122781A1 (es) |
| AU (1) | AU2021299200A1 (es) |
| BR (1) | BR112022026981A2 (es) |
| CA (1) | CA3188350A1 (es) |
| CL (1) | CL2022003810A1 (es) |
| CR (1) | CR20230048A (es) |
| IL (1) | IL299388A (es) |
| MX (1) | MX2022015880A (es) |
| PE (1) | PE20230853A1 (es) |
| TW (2) | TW202334149A (es) |
| WO (1) | WO2022005943A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4172144A2 (en) | 2020-06-30 | 2023-05-03 | Genentech, Inc. | Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety |
| CN114933558B (zh) * | 2022-07-26 | 2022-11-22 | 常熟药明康德新药开发有限公司 | 手性硝基化合物催化还原制备手性氨基化合物的方法 |
| CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种雌激素受体降解剂化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9818B (en) | 1997-01-07 | 1998-07-02 | Abbott Lab | C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion |
| KR102559719B1 (ko) | 2014-12-18 | 2023-07-26 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| PE20211207A1 (es) * | 2018-06-21 | 2021-07-05 | Hoffmann La Roche | Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1- (3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso |
| EP4172144A2 (en) | 2020-06-30 | 2023-05-03 | Genentech, Inc. | Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety |
-
2021
- 2021-06-28 EP EP21745590.6A patent/EP4172144A2/en active Pending
- 2021-06-28 AU AU2021299200A patent/AU2021299200A1/en active Pending
- 2021-06-28 AR ARP210101797A patent/AR122781A1/es unknown
- 2021-06-28 TW TW112102627A patent/TW202334149A/zh unknown
- 2021-06-28 MX MX2022015880A patent/MX2022015880A/es unknown
- 2021-06-28 IL IL299388A patent/IL299388A/en unknown
- 2021-06-28 WO PCT/US2021/039325 patent/WO2022005943A2/en active Application Filing
- 2021-06-28 CN CN202180046838.2A patent/CN115916750A/zh active Pending
- 2021-06-28 TW TW110123552A patent/TWI794856B/zh active
- 2021-06-28 JP JP2022515503A patent/JP7419503B2/ja active Active
- 2021-06-28 CA CA3188350A patent/CA3188350A1/en active Pending
- 2021-06-28 KR KR1020237003166A patent/KR20230031321A/ko unknown
- 2021-06-28 CR CR20230048A patent/CR20230048A/es unknown
- 2021-06-28 US US17/360,593 patent/US11873305B2/en active Active
- 2021-06-28 BR BR112022026981A patent/BR112022026981A2/pt unknown
- 2021-06-28 PE PE2022003059A patent/PE20230853A1/es unknown
-
2022
- 2022-12-29 CL CL2022003810A patent/CL2022003810A1/es unknown
-
2023
- 2023-12-05 US US18/529,046 patent/US20240174678A1/en active Pending
-
2024
- 2024-01-10 JP JP2024001992A patent/JP2024056684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202334149A (zh) | 2023-09-01 |
| CA3188350A1 (en) | 2022-01-06 |
| CN115916750A (zh) | 2023-04-04 |
| KR20230031321A (ko) | 2023-03-07 |
| WO2022005943A3 (en) | 2022-02-17 |
| JP7419503B2 (ja) | 2024-01-22 |
| AU2021299200A1 (en) | 2023-02-23 |
| TWI794856B (zh) | 2023-03-01 |
| US20240174678A1 (en) | 2024-05-30 |
| WO2022005943A2 (en) | 2022-01-06 |
| US11873305B2 (en) | 2024-01-16 |
| JP2023500557A (ja) | 2023-01-10 |
| BR112022026981A2 (pt) | 2023-01-24 |
| PE20230853A1 (es) | 2023-05-29 |
| TW202208363A (zh) | 2022-03-01 |
| US20220002304A1 (en) | 2022-01-06 |
| MX2022015880A (es) | 2023-02-27 |
| CR20230048A (es) | 2023-03-20 |
| IL299388A (en) | 2023-02-01 |
| EP4172144A2 (en) | 2023-05-03 |
| JP2024056684A (ja) | 2024-04-23 |
| CL2022003810A1 (es) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122781A1 (es) | Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridinilo | |
| AR086828A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR108435A1 (es) | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído | |
| AR086829A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR085155A1 (es) | Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos | |
| AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
| AR107633A1 (es) | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico | |
| PE20180030A1 (es) | Compuestos biciclicos de sulfonamida cetona | |
| PE20171511A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| AR066802A1 (es) | Procedimiento para la preparacion de (3-dihalometil-1-metil- pirazol-4-il) carboxamidas n-susttituidas | |
| ECSP099269A (es) | Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble | |
| AR063710A1 (es) | Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden. | |
| AR105494A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR102731A1 (es) | Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor | |
| AR068849A1 (es) | Procedimiento para la preparacion de diamidas de acido sulfonico | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
| BR112015029521A2 (pt) | alquilação com um sulfonato de alquil fluoroalquila | |
| CO6231030A2 (es) | Metodos para preparar compuestos basados en imidazol como potentes inhibidores de respuesta inmune | |
| AR089397A1 (es) | Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica |